Medicare
The Centers for Medicare & Medicaid Services should make its proposed Medicare bundled payment model for radiation oncology voluntary, delay the start date and “balance the risk versus reward equation much more appropriately,” AHA told the agency.
Rebates reduced the growth in Medicare Part D spending for brand-name drugs between 2011 and 2015, but spending for brand-name drugs with rebates still grew by $2 billion or over the five-year period
The AHA appreciates the opportunity to comment on the Centers for Medicare & Medicaid Services’ specialty care models proposed rule, and specifically on the radiation oncology (RO) model. As described in the proposed rule, the RO model would test whether prospective, bundled payments for 90-day…
The Medicare Payment Advisory Commission yesterday and today discussed a number of issues.
The Centers for Medicare & Medicaid Services today issued a final rule with comment period implementing additional program integrity requirements for health care providers and suppliers who participate in certain federal health insurance programs.
The Issue
“Medicare for All” these days – a catch-all label that has become a part of the political dialogue – represents a variety of health coverage proposals that would do everything from establish a national health insurance program with no competition to create a public, Medicare-like option…
On Aug. 2, the Centers for Medicare & Medicaid Services issued its fiscal year (FY) 2020 final rule for the inpatient and long-term care hospital prospective payment systems (PPS). This advisory covers the rule’s LTCH-related provisions. AHA issued a separate Regulatory Advisory on the…
The Centers for Medicare & Medicaid Services July 29 issued a proposed rule that would update physician fee schedule payments for calendar year (CY) 2020.
This supplemental report updates a previous analysis to reflect the revised Medicare-X Choice legislation as introduced in April, 2019.
Medicare will cover nationally Chimeric Antigen Receptor T-cell therapies approved by the Food and Drug Administration to treat certain cancers, as well as off-label uses recommended by compendia approved by the Centers for Medicare & Medicaid Services.